Updated April 5, PHASE 1 PHASE 2 COMBINED PHASES Emergency use in: Canada, European Union, Greenland, Guatemala, Honduras, Iceland, Israel, Kuwait, Mongolia, Norway, Qatar, Singapore, United Kingdom, United States, Vietnam. They engineered the viruses to carry the gene for the coronavirus spike protein. On Dec. 18, the researchers announced a collaboration with Enesi Pharma to formulate a solid version of the vaccine that can be implanted in the skin without a needle.On Jan. 27, 2021, Robin Shattuck, the leader of the project, announced that “it is not the right time to start a new efficacy trial for a further vaccine in the U.K.” Instead of competing with authorized vaccines, they are turning their efforts to making candidates that will work well against emerging variants of the coronavirus. Each particle carries four of the coronavirus proteins. Shafa Pharmed Pars, an Iranian pharmaceutical company, developed a vaccine made of inactivated coronaviruses. On Dec. 30, Sinopharm announced that the vaccine had an efficacy of 79.34 percent, leading the Chinese government to give it approval. A safe and effective COVID-19 vaccine is now available in New York. Storage: Over a year at room temperature They designed their coronavirus vaccine as a pill, which could have made it easier to distribute than syringes for injections. EARLY USE IN KAZAKHSTAN The company projects the vaccine will become available in Vietnam in mid-2021. Approved for use in: Bahrain, China, United Arab Emirates. Updated Jan. 12, PHASE 2 researchers reported 15 cases of the unusual clots in nearly 8 million people who received the vaccine. South Korean vaccine producer EuBiologics launched a Phase 1/2 trial of a protein-based vaccine in late January. Andrew Cuomo said today. They say that such a strategy can help prevent reinfection and limit the spread of new variants. They launched a Phase 1/2 trial of the vaccine, named DS-5670, on March 22. These trials further test the vaccine’s safety. Data not updated on some weekends and holidays. The trial began in February.In November 2020, the Russian government began offering Sputnik V within Russia in a mass vaccination campaign. The Centers for Disease Control and Prevention said on Sunday about 157.5 million people have received at least one dose of a Covid-19 vaccine, including about 123.3 million people who have been fully vaccinated by Johnson & Johnson’s single-dose vaccine or the two-dose series made by Pfizer-BioNTech and Moderna. Emergency use in U.S., E.U., other countries. But the presence of more transmissible virus variants could complicate that progress. Storage: Over a year at room temperature President Biden set a goal on May 4 of reaching 70 percent of adults by July 4. SpyBiotech, a company spun off from the University of Oxford, announced in September that the first volunteers in an Australian Phase 1/2 trial were receiving their Covid-19 vaccine. Type: Muscle injection Updated March 20, PHASE 1 PHASE 2 COMBINED PHASES 0. comments. That assumption turned out to be wrong. In March the companies launched a Phase 1/2 trial, which they anticipate delivering results in the third quarter of 2021. The trial delivered encouraging results: volunteers produced a high level of antibodies with no evidence of harmful side effects.But then the researchers made an unwelcome discovery: some volunteers were getting positive tests for HIV, even though they were not actually infected with that virus. Storage: Up to two years frozen at –4° F (–20° C), and up to three months refrigerated at 36–46° F (2–8° C). On Oct. 23, the company announced they were initiating a Phase 3 trial, eventually recruiting over 25,800 volunteers. EMERGENCY USE IN U.S., ELSEWHERE Albany, N.Y. — Covid-19 vaccinations for 12- to 15-year-olds in New York could start later this week, Gov. began reporting county-level vaccinations on March 26. The researchers registered a Phase 1 trial in Australia on Feb. 8. In addition to their Abdala vaccine, the Center for Genetic Engineering and Biotechnology of Cuba announced on Nov. 26 that it was beginning a Phase 1 trial of a second vaccine, this one delivered as a nasal spray. Their candidate is composed of an adjuvant, along with a section of the spike protein called the receptor-binding domain. At a conference in May, a Medicago official said the company expected to seek authorization for their vaccine in Canada in the third quarter of 2021. EMERGENCY USE IN E.U., ELSEWHERE Johnson & Johnson published a paper on the trial in the New England Journal of Medicine on April 21, 2021.Bahrain became the first country to authorize the vaccine for emergency use on Feb. 25. In 2019, researchers at the University of Hong Kong and Xiamen University created a nasal-spray vaccine for the flu based on a genetically weakened form of the influenza virus. As of Feb. 23, the C.D.C. ImmunityBio launched a Phase 1 trial of a Covid-19 vaccine in October in the United States and another in South Africa in January. This page was created as a community place to share the latest availability for COVID-19 vaccinations, specifically for New York. On Aug. 24, they launched a Phase 1 trial, and on Nov. 16 they moved to Phase 2 with a study on 960 volunteers. Soberana 2 also contains aluminum hydroxide as an adjuvant to boost the immune system.After testing Soberana 2 in animals, Finlay researchers started a Phase 1 trial in October 2020, followed by a Phase 2 trial in December. New York-based Codagenix develops vaccines based on live attenuated viruses, but with a twist: they create the viruses from scratch. Cahill-Keyes map projection by Gene Keyes. After a series of promising experiments on animals, they began injecting volunteers for a Phase 1 trial in early October. Several states in the South and West, for example, have vaccinated a smaller share of their population with a first or single dose than in other regions. On Feb. 11, Indian regulators gave Bharat Biotech approval to launch a Phase 1 trial of a vaccine delivered as a nasal spray. The researchers inactivated the NDVs with chemicals and combined them with immune-boosting chemicals called adjuvants. Last June, Covaxin became the first coronavirus vaccine created in India to go into clinical trials.The phase 1/2 trial showed that the vaccine didn’t cause any serious side effects while producing antibodies to the coronavirus, and a follow-up study confirmed these results. On March 3, 2021, the Finlay Vaccine Institute registered a Phase 3 trial for Soberana 2, with plans to recruit 44,010 participants in Havana. In response to the pandemic, they developed an mRNA vaccine against the coronavirus. EARLY USE IN RUSSIA Efficacy: Unknown After positive results from a Phase 1 trial, Finlay received approval to begin a Phase 2 trial among Covid-19 survivors on April 9. In April, the South Korean biotech company Cellid began to develop a vaccine for Covid-19. AstraZeneca is preparing its application to the F.D.A. Three decades ago, the German Center for Infection Research developed a smallpox vaccine from a harmless virus called Modified Vaccinia Ankara, or MVA for short. for full authorization.Even while it was running clinical trials, AstraZeneca reached agreements with a number of manufacturers in order to produce billions of doses of Vaxzevria. But the company struggled to get the vaccine’s complex manufacturing up and running. Taiwan-based vaccine manufacturer Adimmune got permission to launch a Phase 1 trial on Aug. 20. The Serum Institute of India, which licensed the technology from SpyBiotech, is running the trials. On Aug. 26, the Vector Institute, a Russian biological research center, registered a Phase 1/2 trial for a coronavirus vaccine they call EpiVacCorona. Approved in Turkmenistan. APPROVED IN CHINA Vaccines that deliver one or more of the coronavirus’s own genes into our cells to provoke an immune response. The Russian Ministry of Health said Sputnik Light provides sufficient protection on its own to be used without a second injection. On Feb. 3, Vaxart announced that the trial revealed no serious safety concerns. The Covid-19 Vaccine Guide for Immigrants in New York. Updated Feb. 8, PHASE 1 PHASE 2 COMBINED PHASES The vaccine designers hope to create a new version of the vaccine with proteins from other coronaviruses to offer protection that extends beyond Covid-19. Comirnaty is also one of several vaccines being tested in an Oxford study to gauge how well alternating doses promote immunity.Dr. Updated May 5, PHASE 1 It was cleared for human testing late last year by the Canadian government. They hope the combination will enable the vaccine to produce immunity that’s both fast and long-lasting. In early 2020, Imperial College London researchers developed a “self-amplifying” RNA vaccine for Covid-19, which boosted production of a viral protein to stimulate the immune system. Type: Muscle injection Despite promising early results, support for the research disappeared. approval for their vaccine. Below is a list of all vaccines that have reached trials in humans, along with a selection of promising vaccines being tested in animals. Vaccine name: ZyCoV-D Instead, it has moved forward with a trial with the Dynavax adjuvant. The efficacy determined from the Phase 3 trials has yet to be published. They began using Johnson & Johnson’s instead.In August 2020, the federal government agreed to pay Johnson & Johnson $1 billion for 100 million doses if the vaccine was authorized. The researchers registered a Phase 2 trial on April 13. New one-shot vaccine sites at major New York City transit hubs to offer free 7-day MetroCards, train tickets to recipients. On Dec. 22, the company registered a Phase 1 clinical trial of a single dose of the vaccine They began recruiting volunteers on Feb. 25. Starting April 2, smaller arts, entertainment and event venues can start using it. They added two coronavirus genes to the virus — one for the spike protein, and one for another protein called nucleocapsid. Updated March 25, PHASE 2 Updated March 4, PHASE 3 EMERGENCY USE IN INDIA, ELSEWHERE Dose: 2 doses, 3 weeks apart After partnering with GSK, they launched a Phase 1/2 trial of the vaccine in February. Updated Jan. 13, PHASE 1 In a Phase 1 trial, researchers are now testing the vaccine on 50 volunteers. typically reports data as of 6 a.m. each day. After successful experiments in animals, a Phase 1 trial was launched in the United Kingdom in January. reported about 4.6 million new doses administered, including about 1.6 million doses that were reported after the 6 a.m. cutoff, resulting in a visible spike. Replicating adenoviruses could make the vaccine dangerous. They then infect insect cells with the virus, causing them to make the molecule in huge amounts. Updated Jan. 12, PHASE 1 The vaccine, called CORVax12, consists of a loop of DNA that encodes both the spike protein and IL-12. The company found that the vaccine protects monkeys from the coronavirus. They are running the trial in collaboration with the Government Pharmaceutical Organization, a Thai state-run drug manufacturer. This data is not available for all states, and is incomplete in others, artificially lowering the published vaccination rates for some counties. Notes and corrections: Early versions of the tracker combined two vaccines by Sinopharm into one entry, before subsequent reporting confirmed they were two different vaccines. The South Korean vaccine company SK Bioscience licensed the vaccine, called GBP510. Updated May 6, PHASE 1 PHASE 2 COMBINED PHASES Efficacy: Unknown Nikkei Asia reported that Nanogen is considering Phase 3 trials in Bangladesh, India, and Indonesia. Regulators authorized Johnson & Johnson’s one-dose vaccine in February, but recommended a pause in its use on April 13 because of reports of blood clots in a small number of patients. In addition, the Governor announced more than 17 million vaccine doses have been administered in New York State. To make the vaccine, researchers started off with another virus, called respiratory syncytial virus (RSV for short). According to a new U.S. census estimate, some 30 million American adults who are open to getting a coronavirus vaccine have not managed to actually do so. APPROVED IN BRAZIL Clover’s formula looks to be especially durable; the vaccine can sit out at room temperature for a month and remain viable.Clover launched a Phase 1 trial last June, and in December the company announced that the vaccine triggered a high level of antibodies. Efficacy: 65.28% The C.D.C. Their vaccine Covaxin, made of inactivated coronaviruses, is already in emergency use in India. Less than two months later, on Oct. 14, Vladimir Putin announced that Russia has granted regulatory approval to the vaccine, making it the second one to receive that designation after the Gamaleya Institute’s Sputnik V vaccine.A Phase 3 trial began in November, and as of Dec. 15, the Interfax News Agency reported that 1,438 volunteers had received the vaccine.In January, Russia launched a mass vaccination campaign that included EpiVacCorona.. Dose: 2 doses, 2 weeks apart Some states, including Alaska, North Dakota and Utah, are supposed to receive supplements for tribal governments that have elected to receive their vaccines through the state, rather than through the federal Indian Health Service. Along with their Beijing Institute vaccine, Sinopharm also tested an inactivated virus vaccine developed by the Wuhan Institute of Biological Products. All New Yorkers 16 years of age and older are now eligible to be vaccinated. On April 1, 2021, French researchers at OSE Immunotherapeutics announced they had received approval to launch a Phase 1 trial of a vaccine, called CoVepiT, in Belgium. Emergency use in: Albania NEW, Algeria, Angola, Antigua and Barbuda, Argentina, Armenia, Azerbaijan, Bahrain, Bangladesh NEW, Belarus, Bolivia, Bosnian Serb Republic, Cameroon, Congo Republic, Djibouti, Egypt, Honduras, Gabon, Ghana, Guatemala, Guinea, Guyana, Hungary, India, Iran, Iraq, Jordan, Kazakhstan, Kenya, Kyrgyzstan, Laos, Lebanon, Mali, Mauritius, Mexico, Moldova, Mongolia, Montenegro, Morocco, Myanmar, Namibia, Nepal, Nicaragua, North Macedonia, Pakistan, Palestinian Authority, Panama, Paraguay, Philippines, San Marino, Slovakia, Sri Lanka, St. Vincent and the Grenadines, Serbia, Seychelles, Syria, Tunisia, Turkey NEW, Turkmenistan, United Arab Emirates, Uzbekistan, Venezuela, Vietnam, Zimbabwe. Efficacy: Unknown The Bureau's mission is to reduce illnesses, complications and deaths from vaccine-preventable diseases in New Yorkers of … The vaccine is based on a combination of two strains of adenoviruses, called Ad5 and Ad35. In July a Phase 3 trial began in the United Arab Emirates in July, and in Morocco and Peru the following month.On Sept. 14, the U.A.E. ALBANY — New York’s coronavirus vaccine task force has approved the statewide use of Pfizer’s coronavirus vaccine to kids ages 12 to 15, starting Thursday. In the wake of that reporting, the Department of Justice began investigating the company, while a number of shareholder lawsuits were brought against Vaxart, its executives and its board.In October, the company began giving the pill to volunteers in a Phase 1 clinical trial. The French vaccine maker Valneva created a vaccine from chemically inactivated coronaviruses, using an adjuvant from Dynavax. On March 22, Japan’s KM Biologics announced that it had begun a Phase 1/2 trial of its inactivated vaccine candidate, called KD-414. Emergency use validation from the World Health Organization. On Nov. 2, the Canadian company Symvivo announced they had administered a DNA vaccine to their first volunteer in a Phase 1 trial. Updated April 26, PHASE 3 The researchers hope that this combination will produce a better immune response than two doses of either vaccine. Vaccine name: Ad26.COV2.S On Dec. 10, 2020, a vaccine from Australia’s University of Queensland was the first to be abandoned after entering a clinical trial. A Phase 3 trial involving up to 48,000 participants was launched on March 18.Before the Phase 3 trial delivered its results, however, the Cuban government began rolling out Abadla on May 12 in a mass vaccination campaign, in the hopes of reining in a surge of cases. Emergency use in: Argentina, Australia, Botswana, Brunei, Canada, Chile, Colombia, Costa Rica, Ecuador, European Union, Greenland, Guatemala, Hong Kong, Iceland, Iraq, Israel, Japan, Jordan, Kuwait, Lebanon, Liechtenstein, Malaysia, Maldives, Mexico, Moldova, Monaco, Mongolia, Norway, North Macedonia, Oman, Panama, Peru, Philippines, Qatar, Serbia, Singapore, South Africa, South Korea, Tunisia, Turkey, Ukraine, United Arab Emirates, United Kingdom, United States, Uruguay. Antibodies induced by the Pfizer/BioNTech and Moderna vaccines and the antibody therapy from Regeneron Pharmaceuticals all are able to neutralize a coronavirus variant on the rise in New York, lab … Canada-based Medicago, partly funded by the cigarette maker Philip Morris, grows vaccines in a plant called Nicotiana benthamiana, a wild species related to tobacco. Additional reporting by Farnaz Fassihi, Denise Grady, Andrew E. Kramer, Matthew Kristoffersen, Hari Kumar, Cao Li, Jess Ruderman and Carlos Tejada. Type: Muscle injection The researchers estimated that the vaccine had an efficacy rate of 94.1 percent. 116,093 doses have been administered across the state's vast distribution network in the last 24 hours, and nearly 1 million … Approved for use in: Switzerland. Entos instead chose the gene for nucleocapsid, a protein that sits inside the virus’s membrane. It finally launched on Dec. 28 and is expected to deliver results in spring 2021. Updated May 1, PHASE 1 PHASE 2 COMBINED PHASES The researchers engineered NDV to carry the gene for a modified version of the coronavirus spike protein called HexaPro, developed at the University of Texas. Last January, they began developing a vaccine for the coronavirus.The United States government bankrolled Moderna’s efforts, providing nearly $1 billion in support. Emergency use validation from the World Health Organization. On Feb. 25, China announced the approval of the Wuhan vaccine for general use. EARLY OR LIMITED APPROVAL: Many countries have procedures for providing emergency authorizations for vaccines, based on preliminary evidence that they are safe and effective. EMERGENCY USE IN U.S., ELSEWHERE In an unpublished study, they found that the vaccine pill not only dramatically reduced the amount of coronavirus in sick hamsters, but also protected them from two important symptoms of the disease: weight loss and swollen lungs.The company’s stock price increased 3,600 percent in the first half of 2020. The New York State Bar Association on Saturday passed a resolution urging the state to consider making it mandatory for all New Yorkers to undergo COVID-19 vaccination when a … On Feb. 14, they announced they would start trials on children as young as six. Another combination trial is currently underway between the Oxford-AstraZeneca, Pfizer, Moderna and Novavax vaccines. Last year they constructed a vaccine for Covid-19 that presents a number of targets in the coronavirus for attack.The researchers constructed a piece of DNA that encodes the entire spike protein of the coronavirus. Some jurisdictions have been more efficient than others at administering their doses from the federal government. Two days later, the Biden administration said it would fund a substantial expansion of Biological E’s manufacturing capability. The name refers to women who fought in Cuba’s nineteenth-century wars of independence. Those living and working in New York's state nursing homes will be offered the COVID vaccine after it was revealed only 56 percent of staff in NYC have had it. As a result, the company only delivered 4 million doses to the United States after authorization, shipping them from its factory in the Netherlands.On April 13 the U.S. government recommended a pause in using the vaccine while it investigated reports of rare blood clots. Efficacy: Unknown A Phase 2 trial followed on 750 volunteers, which led the researchers to select a two-week spacing between the two doses of the vaccine. Japan-based researchers at Daiichi Sankyo have developed an mRNA vaccine against the coronavirus in collaboration with the University of Tokyo. As it works towards getting the Baltimore facility certified, it is also getting help from Merck, which announced on March 2 it would assist Johnson & Johnson with manufacturing the vaccine.The European Union reached a similar deal on Oct. 8, 2020 for 200 million doses. Type: Muscle injection Vietnam news agencies announced that Nanocovax entered Phase 2 trials in February. In a study posted online in April, researchers studied antibodies from people who had received the vaccine. On Jan. 3, 2021 the Indian government gave Zydus Cadila permission to advance to a Phase 3 trial with 30,000 volunteers. of all residents that are fully vaccinated, Pct. But on April 1, CanSino’s chief scientific officer said that the efficacy of its vaccine could drop over time. At least 15 million doses of Johnson & Johnson’s vaccine were contaminated at the factory. Investments from the Coalition for Epidemic Preparedness supported the development of manufacturing that could lead to the production of a billion doses a year. They began Phase 1/2 trials on June 15, partnering with Morningside Ventures to manufacture and distribute the vaccine through a new company called VacEquity Global Health. notes that total doses administered are based on the location where the vaccine was given, and that in limited cases, people might get a vaccine outside of their place of residency. Bharat researchers found that antibodies produced by Covaxin were modestly less effective at sticking to the variant virus. Researchers rewrite the genome of viruses, introducing hundreds of mutations. While the pill produced a response from T cells, it didn’t produce encouraging neutralizing antibodies.